Barclays PLC Acquires 13,903 Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

Barclays PLC increased its position in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE - Free Report) by 1,275.5% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,993 shares of the biopharmaceutical company's stock after purchasing an additional 13,903 shares during the period. Barclays PLC's holdings in Xenon Pharmaceuticals were worth $590,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Blue Trust Inc. grew its position in shares of Xenon Pharmaceuticals by 174.7% during the third quarter. Blue Trust Inc. now owns 1,008 shares of the biopharmaceutical company's stock worth $39,000 after purchasing an additional 641 shares in the last quarter. nVerses Capital LLC bought a new stake in shares of Xenon Pharmaceuticals during the third quarter valued at approximately $102,000. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Xenon Pharmaceuticals by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company's stock worth $106,000 after acquiring an additional 487 shares during the last quarter. Quarry LP grew its stake in Xenon Pharmaceuticals by 207.7% during the second quarter. Quarry LP now owns 4,000 shares of the biopharmaceutical company's stock valued at $156,000 after acquiring an additional 2,700 shares in the last quarter. Finally, Vestcor Inc purchased a new stake in Xenon Pharmaceuticals in the 3rd quarter worth $327,000. 95.45% of the stock is currently owned by institutional investors.

Xenon Pharmaceuticals Stock Down 2.8 %

XENE traded down $1.10 during trading hours on Friday, reaching $38.52. 469,451 shares of the company's stock traded hands, compared to its average volume of 416,805. The firm has a 50-day moving average price of $40.48 and a 200 day moving average price of $40.71. Xenon Pharmaceuticals Inc. has a 52-week low of $35.53 and a 52-week high of $50.99. The firm has a market capitalization of $2.94 billion, a PE ratio of -13.66 and a beta of 1.20.

Xenon Pharmaceuticals (NASDAQ:XENE - Get Free Report) last issued its earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.81) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.82) by $0.01. During the same quarter in the previous year, the business earned ($0.73) EPS. Equities analysts predict that Xenon Pharmaceuticals Inc. will post -3.13 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have issued reports on XENE shares. Raymond James reaffirmed an "outperform" rating and issued a $50.00 price objective on shares of Xenon Pharmaceuticals in a research note on Thursday, October 10th. Needham & Company LLC reiterated a "buy" rating and issued a $60.00 price target on shares of Xenon Pharmaceuticals in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $53.00 target price on shares of Xenon Pharmaceuticals in a report on Thursday, December 12th. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, Xenon Pharmaceuticals currently has a consensus rating of "Buy" and an average price target of $56.00.

Insider Transactions at Xenon Pharmaceuticals

In related news, Director Gary Patou sold 4,891 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $41.08, for a total value of $200,922.28. Following the transaction, the director now owns 23,573 shares of the company's stock, valued at $968,378.84. This represents a 17.18 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Sherry Aulin sold 18,709 shares of Xenon Pharmaceuticals stock in a transaction on Wednesday, December 18th. The shares were sold at an average price of $41.21, for a total value of $770,997.89. The disclosure for this sale can be found here. Corporate insiders own 5.52% of the company's stock.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.